DDInter1232 DDInter1055
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries.
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Mitomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Mitomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Mitomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Mitomycin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Mitomycin {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) Levofloxacin
Mitomycin {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Levofloxacin
Mitomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Ciprofloxacin
Ciprofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Mitomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Mitomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Lomefloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Mitomycin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ciprofloxacin
Ciprofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Levofloxacin (Compound)
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Levofloxacin (Compound)
Mitomycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Levofloxacin (Compound)
Mitomycin (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Levofloxacin (Compound)
Mitomycin (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Levofloxacin (Compound)
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Ciprofloxacin (Compound) and Ciprofloxacin (Compound) resembles Levofloxacin (Compound)
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Mitomycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ciprofloxacin (Compound) and Ciprofloxacin (Compound) resembles Levofloxacin (Compound)